Table 1.
Demographics by age group
| Age group | P‐value | ||
|---|---|---|---|
| ≤18 y (n = 14) | >18 y (n = 19) | ||
| AGE, median (range) | 17 (7‐18) | 24 (19‐38) | |
| Treatment location, n (%) | |||
| Children's hospital (DCH) | 12 (85.7%) | 1 (5.3%) | <0.001 |
| Adult hospital (KCI) | 2 (14.3%) | 18 (94.7%) | |
| Sex, n (%) | |||
| Male | 8 (57.1%) | 13 (68.4%) | 0.716 |
| Female | 6 (42.9%) | 6 (31.6%) | |
| Race, n (%) | |||
| Caucasian | 10 (71.4%) | 16 (84.2%) | 0.422 |
| Non‐Caucasian | 4 (28.6%) | 3 (15.8%) | |
| Ethnicity, n (%) | |||
| Hispanic | 12 (85.7%) | 17 (89.5%) | 1.000 |
| Non‐Hispanic | 2 (14.3%) | 2 (10.5%) | |
| Tumor location, n (%) | |||
| Appendicular (extremity, limb girdle) | 12 (85.7%) | 12 (63.2%) | 0.241 |
| Axial (spine, pelvis, head/neck) | 2 (14.3%) | 7 (36.8%) | |
| Stage at diagnosis, n (%) | |||
| Localized and resectable | 12 (85.7%) | 13 (68.4%) | 0.416 |
| Unresectable or metastatic | 2 (14.3%) | 6 (31.6%) | |
| Initial eGFR, median (range) | 114 (87‐157) | 124 (96‐144) | 0.051 |
| Doses of HDMTX received, n (%) | |||
| 12 | 10 (71.4%) | 4 (21.0%) | 0.006 |
| <12 | 4 (28.6%) | 15 (79.0%) | |
| Histologic response, n (%) | |||
| ≥90% | 7 (50%) | 5 (26.3%) | 0.218 |
| <90% | 7 (50%) | 11 (57.9%) | |
| Never resected | 0 (0%) | 3 (9.1%) | |